Fosun: Foreign Media Reports about “Regulatory Authorities Asking Banks to Examine their Exposure to Fosun” are Completely False

HONG KONG, Sept. 14, 2022 /PRNewswire/ — In response to foreign media reports about “Chinese regulatory authorities asking banks and some of the state-owned companies to examine their exposure to Fosun” on 13 September, Fosun said such reports are completely false.

It is understood that Fosun has sought confirmation from regulatory authorities through multiple channels. The China Banking and Insurance Regulatory Commission (CBIRC) has not asked commercial banks to check about their financial exposure on Fosun, and many commercial banks that cooperate with Fosun have never received relevant notices.

Gong Ping, Executive President and CFO of Fosun International, said, “Fosun’s recent seemingly frequent reductions in shareholdings and divestments are a continuation of its financial strategy of balancing investment and divestment in the past few years. Fosun has been dynamically sorting and optimizing its asset portfolios. Such moves are not just for coping with the current market environment. However, we noticed that the complex external environment has raised public opinion on the disposal of the Group’s assets, resulting in a one-sided interpretation of such asset disposal, while neglecting the Group’s general principle of asset optimization, which is our long-term dynamic asset optimization.”

According to the interim results announced on 30 August, Fosun’s four major business segments of Health, Happiness, Wealth, and Intelligent Manufacturing demonstrated resilience. In the first half of the year, Fosun achieved sustainable revenue growth, its total revenue reached RMB82.89 billion, representing a year-on-year increase of 17.7%. Its enterprise operation profit increased by 35.5% year-on-year. Meanwhile, the Group’s funds remained stable. As at the end of the reporting period, cash, bank balances and term deposits were abundant, amounting to RMB117.65 billion; the adjusted NAV remained stable at HK$24.2 per share.

Subscribe on LinkedIn

PR Newswire is solely responsible for the content of the above news submissions. If there are any violations of laws, violations of the membership terms of this website, or the risk of infringing on the rights of third parties, PR Newswire will be solely responsible for legal and damage compensation. Responsibility has nothing to do with MedicaEx.

Are you in?

Subscribe to receive exclusive content and notifications to your inbox

We're committed to your privacy. MedicaEx uses the information you provide to us to contact you about our relevant content, products, and services. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.